This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zung, A. Articles by Zadik, Z. Search for Related Content PubMed PubMed Citation Articles by Zung, A. Articles by Zadik, Z.

Glibenclamide Treatment in Permanent Neonatal Diabetes Mellitus due to an Activating Mutation in Kir6.2

Pediatric Endocrinology Unit (A.Z., Z.Z.), Kaplan Medical Center, Affiliated with Hadassah Medical School, The Hebrew University of Jerusalem, Israel; Endocrinology and Metabolism Service (B.G.), Internal Medicine Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Institute for Endocrinology and Diabetes (R.N.), Schneider Children’s Medical Center of Israel

Address all correspondence and requests for reprints to: Amnon Zung, Pediatric Endocrinology Unit, Affiliated with Hadassah Medical School, The Hebrew University of Jerusalem, Rehovot 76100, Israel. E-mail: amzung2{at}bezeqint.net

Abstract

Permanent neonatal diabetes mellitus (PNDM) is a rare form of diabetes characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Recently, activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 were identified in 10 PNDM patients. Tolbutamide-stimulated insulin secretion, demonstrated in 3 of these patients suggested that some PNDM patients may respond to oral sulfonylurea treatment. In this report, we describe an infant with PNDM due to an arginine-to-histidine substitution at position 201 (R201H) of the gene encoding Kir6.2. After insulin pump therapy for six months, he was shifted to oral glybenclamide therapy at a daily dose of 0.8 mg/kg. Basal c-peptide level increased by two fold during glybenclamide treatment, but no further elevation was observed following intravenous glucose administration. Outpatient, continuous glucose monitoring while on a normal infant diet demonstrated a marked improvement in glycemic control. This study demonstrates the feasibility of oral sulfonylurea treatment in PNDM patients with Kir6.2 mutations even during infancy, and the superiority of this approach over insulin administration.

This article has been cited by other articles:

				L. Aguilar-Bryan and J. Bryan Neonatal Diabetes Mellitus Endocr. Rev., May 1, 2008; 29(3): 265 - 291. [Abstract] [Full Text] [PDF]

				B. Glaser Insulin Mutations in Diabetes: The Clinical Spectrum Diabetes, April 1, 2008; 57(4): 799 - 800. [Full Text] [PDF]

				J. C. Koster, F. Cadario, C. Peruzzi, C. Colombo, C. G. Nichols, and F. Barbetti The G53D Mutation in Kir6.2 (KCNJ11) Is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood that Is Improved with Sulfonylurea Therapy J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1054 - 1061. [Abstract] [Full Text] [PDF]

				F. M. Ashcroft ATP-sensitive K+ channels and disease: from molecule to malady Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E880 - E889. [Abstract] [Full Text] [PDF]

				K. Shimomura, F. Horster, H. de Wet, S. E. Flanagan, S. Ellard, A. T. Hattersley, N. I. Wolf, F. Ashcroft, and F. Ebinger A novel mutation causing DEND syndrome: A treatable channelopathy of pancreas and brain Neurology, September 25, 2007; 69(13): 1342 - 1349. [Abstract] [Full Text] [PDF]

				X. Geng, L. Li, R. Bottino, A. N. Balamurugan, S. Bertera, E. Densmore, A. Su, Y. Chang, M. Trucco, and P. Drain Antidiabetic sulfonylurea stimulates insulin secretion independently of plasma membrane KATP channels Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E293 - E301. [Abstract] [Full Text] [PDF]

				S. E. Flanagan, A.-M. Patch, D. J.G. Mackay, E. L. Edghill, A. L. Gloyn, D. Robinson, J. P.H. Shield, K. Temple, S. Ellard, and A. T. Hattersley Mutations in ATP-Sensitive K+ Channel Genes Cause Transient Neonatal Diabetes and Permanent Diabetes in Childhood or Adulthood Diabetes, July 1, 2007; 56(7): 1930 - 1937. [Abstract] [Full Text] [PDF]

				R. Masia, J. C. Koster, S. Tumini, F. Chiarelli, C. Colombo, C. G. Nichols, and F. Barbetti An ATP-Binding Mutation (G334D) in KCNJ11 Is Associated With a Sulfonylurea-Insensitive Form of Developmental Delay, Epilepsy, and Neonatal Diabetes Diabetes, February 1, 2007; 56(2): 328 - 336. [Abstract] [Full Text] [PDF]

				E. R. Pearson, I. Flechtner, P. R. Njolstad, M. T. Malecki, S. E. Flanagan, B. Larkin, F. M. Ashcroft, I. Klimes, E. Codner, V. Iotova, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med., August 3, 2006; 355(5): 467 - 477. [Abstract] [Full Text] [PDF]

				A. S. Slingerland and A. T. Hattersley Activating Mutations in the Gene Encoding Kir6.2 Alter Fetal and Postnatal Growth and Also Cause Neonatal Diabetes J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2782 - 2788. [Abstract] [Full Text] [PDF]

				E. Hathout, J. Mace, G. I. Bell, and P. R. Njolstad Treatment of Hyperglycemia in a 7-Year-Old Child Diagnosed With Neonatal Diabetes. Diabetes Care, June 1, 2006; 29(6): 1458 - 1458. [Full Text] [PDF]

				P. Proks, A. L. Arnold, J. Bruining, C. Girard, S. E. Flanagan, B. Larkin, K. Colclough, A. T. Hattersley, F. M. Ashcroft, and S. Ellard A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes Hum. Mol. Genet., June 1, 2006; 15(11): 1793 - 1800. [Abstract] [Full Text] [PDF]

				K. Shimomura, C. A.J. Girard, P. Proks, J. Nazim, J. D. Lippiat, F. Cerutti, R. Lorini, S. Ellard, A. T. Hattersley, F. Barbetti, et al. Mutations at the Same Residue (R50) of Kir6.2 (KCNJ11) That Cause Neonatal Diabetes Produce Different Functional Effects Diabetes, June 1, 2006; 55(6): 1705 - 1712. [Abstract] [Full Text] [PDF]

				C.-W. Lin, Y.-W. Lin, F.-F. Yan, J. Casey, M. Kochhar, E. B. Pratt, and S.-L. Shyng Kir6.2 Mutations Associated With Neonatal Diabetes Reduce Expression of ATP-Sensitive K+ channels: Implications in Disease Mechanism and Sulfonylurea Therapy Diabetes, June 1, 2006; 55(6): 1738 - 1746. [Abstract] [Full Text] [PDF]

				E. L. Edghill, R. J. Dix, S. E. Flanagan, P. J. Bingley, A. T. Hattersley, S. Ellard, and K. M. Gillespie HLA Genotyping Supports a Nonautoimmune Etiology in Patients Diagnosed With Diabetes Under the Age of 6 Months Diabetes, June 1, 2006; 55(6): 1895 - 1898. [Abstract] [Full Text] [PDF]

				A. T. Hattersley and E. R. Pearson Minireview: Pharmacogenetics and Beyond: The Interaction of Therapeutic Response, {beta}-Cell Physiology, and Genetics in Diabetes Endocrinology, June 1, 2006; 147(6): 2657 - 2663. [Abstract] [Full Text] [PDF]

				J. C. Koster, M. A. Permutt, and C. G. Nichols Diabetes and Insulin Secretion: The ATP-Sensitive K+ Channel (KATP) Connection Diabetes, November 1, 2005; 54(11): 3065 - 3072. [Abstract] [Full Text] [PDF]

				P. Proks, C. Girard, and F. M. Ashcroft Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP Hum. Mol. Genet., September 15, 2005; 14(18): 2717 - 2726. [Abstract] [Full Text] [PDF]

				A. T. Hattersley and F. M. Ashcroft Activating Mutations in Kir6.2 and Neonatal Diabetes: New Clinical Syndromes, New Scientific Insights, and New Therapy Diabetes, September 1, 2005; 54(9): 2503 - 2513. [Abstract] [Full Text] [PDF]

				J. C. Koster, M. S. Remedi, C. Dao, and C. G. Nichols ATP and Sulfonylurea Sensitivity of Mutant ATP-Sensitive K+ Channels in Neonatal Diabetes: Implications for Pharmacogenomic Therapy Diabetes, September 1, 2005; 54(9): 2645 - 2654. [Abstract] [Full Text] [PDF]

				L. Li, X. Geng, M. Yonkunas, A. Su, E. Densmore, P. Tang, and P. Drain Ligand-dependent Linkage of the ATP Site to Inhibition Gate Closure in the KATP Channel J. Gen. Physiol., August 29, 2005; 126(3): 285 - 299. [Abstract] [Full Text] [PDF]

				T. Yorifuji, K. Nagashima, K. Kurokawa, M. Kawai, M. Oishi, Y. Akazawa, M. Hosokawa, Y. Yamada, N. Inagaki, and T. Nakahata The C42R Mutation in the Kir6.2 (KCNJ11) Gene as a Cause of Transient Neonatal Diabetes, Childhood Diabetes, or Later-Onset, Apparently Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3174 - 3178. [Abstract] [Full Text] [PDF]

				A. L. Gloyn, F. Reimann, C. Girard, E. L. Edghill, P. Proks, E. R. Pearson, I. K. Temple, D. J.G. Mackay, J. P.H. Shield, D. Freedenberg, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11 Hum. Mol. Genet., April 1, 2005; 14(7): 925 - 934. [Abstract] [Full Text] [PDF]

				E. Codner, S. Flanagan, S. Ellard, H. Garcia, and A. T. Hattersley High-Dose Glibenclamide Can Replace Insulin Therapy Despite Transitory Diarrhea in Early-Onset Diabetes Caused by a Novel R201L Kir6.2 Mutation Diabetes Care, March 1, 2005; 28(3): 758 - 759. [Full Text] [PDF]